Endo Closes Auxilium Pharmaceuticals Acquisition.
29 January 2015 - Irish drugmaker Endo International plc (NASDAQ: ENDP) (TSX: ENL) has completed the acquisition of US-based Auxilium Pharmaceuticals, Inc. in a transaction valued at USD 2.6bn when announced on 9 October 2014, the company said on Thursday.
The closing of the transaction follows the approval of the acquisition by Auxilium's shareholders on January 27, 2015, and the receipt of all required regulatory approvals.
According to Endo, the combined company will provide an expanded platform to accelerate the evolution and growth of Endo's US Branded Pharmaceuticals business.
With the acquisition complete, Endo's portfolio has a broader offering of urology and orthopedic products, it said.
Endo International develops, manufactures, markets, and distributes quality branded pharmaceutical, generic pharmaceutical, over the counter medications and medical device products through its operating companies. Endo has global headquarters in Dublin, Ireland, and US headquarters in Malvern, PA.
Target: Auxilium Pharmaceuticals, Inc
Buyer: Endo International plc
Deal size in USD: 2.6bn
Type: Corporate acquisition
Financing: Cash and Stock
Buyer advisor: , ,